Skip to main content
. 2020 Dec 11;45(2):469–480. doi: 10.3892/or.2020.7897

Figure 5.

Figure 5.

NACC1 is a target of miR-423-5p in MCL. (A) Predicted binding site of miR-423-5p in NACC1. (B) Luciferase reporter assay of NACC1-WT or NACC1-MUT co-transfected into MCL JVM-2 and Z-138 cells with miR-423-5p mimics or miR-NC. ***P<0.001, compared with the miR-NC group; ns, not significant. (C) The miR-423-5p expression in MCL cells transfected with miR-3184-5p mimics or inhibitors as assessed by qPCR. ***P<0.001, compared with the miR-NC or anti-miR-NC group. (D) NACC1 at the protein and mRNA levels in MCL JVM-2 and Z-138 cells transfected with miR-3184-5p mimics or inhibitors as assessed by western blotting and qPCR. ***P<0.001, compared with the miR-NC or anti-miR-NC group. (E) Pearson correlation analysis between miR-423-5p and NACC1 expression levels in plasma samples of MCL patients. (F) Kaplan-Meier curves for overall survival and disease-free survival of patients with low and high expression of miR-423-5p (miR-423-5p high, n=30; miR-423-5p low, n=30). Data are presented as mean ± SD of three independent experiments. MCL, mantle cell lymphoma; NACC1, nucleus accumbens-associated 1; WT, wild-type; MUT, mutant.